Detail akcie Moderna Rg online

Business Summary: Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Moderna Inc revenues decreased 53% to $3.24B. Net loss decreased 24% to $3.56B. Revenues reflect Rest of the World segment decrease of 76% to $853M, Europe segment decrease of 56% to $598M. Lower net loss reflects Valuation of Inventory - Gain/Loss decrease of 78% to $495M (expense), General and administrative decrease of 38% to $888M (expense).